{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-049634","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2022-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.993077+00:00","generated_at":"2026-06-26T04:58:22.549275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M","bullets":["Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.","U.S. active implanting centers grew to 56 from 19; sales territories expanded to 17 from 6 year-over-year.","Cash $131.2M at Mar 31, 2022; full-year 2022 revenue guidance $20-23M; Q2 expected $4.5-5M.","Received FDA approval for new tablet-form factor programmer in April 2022.","Gross margin improved to 77% from 70%; R&D $2.3M (+29%), SG&A $10.8M (+142%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-049634","json":"https://secwatch.observer/filing/0001104659-22-049634.json","markdown":"https://secwatch.observer/filing/0001104659-22-049634.md","text":"https://secwatch.observer/filing/0001104659-22-049634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/0001104659-22-049634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/tm2213448d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:58:22.549275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}